News feeds
Email news|
TheraVitae Presents Positive Stem Cell Trial Results at American Heart Association Convention |
| Written by Jon Bradshaw | |
| Wednesday, 15 November 2006 | |
|
Summary: American Heart Association - TheraVitae presented the final results of a clinical trial of patients suffering from severe angina pectoris. The data shows the patients improved significantly after receiving VesCell TM autologous adult stem cell therapy. Chicago, IL, 15 November, 2006 - TheraVitae, an international biotechnology company and the producer of VesCellTM adult stem cell therapy for heart disease, presented the final results from its first clinical study at the American Heart Association Scientific Sessions this week in Chicago. The results of the study show that the therapy has a high safety profile and is effective in alleviating severe angina pectoris in patients without any other therapeutic option. The study, evaluating the safety and efficacy of intracoronary administration of VesCellTM to patients suffering from severe angina pectoris, was conducted in conjunction with Her Majesty’s Cardiac Center at Siriraj Medical Hospital in Bangkok, Thailand. By using sophisticated tissue culture technology facilitating the isolation, expansion and differentiation of angiogenic cell precursors (ACPs) to an amount sufficient to induce blood vessel formation in the heart, the scientists at TheraVitae have developed VesCellTM, which is used now by doctors in Thailand and Singapore for patients suffering from severe heart disease. Cells are isolated from the blood, processed outside the body and then administered to the patient into regions of the heart suffering from reduced blood supply. Prof. Damras Tresukosol MD Director of Cardiology at the Siriraj Hospital, Mahidol University in Bangkok and the Principal Investigator of the trial, presented the results which showed significant improvement in most patients at six month follow-up:
The results are a major step toward proving the safety and efficacy of VesCellTM therapy, and demonstrate the reliability of TheraVitae's cell manufacturing process. Moreover, they illustrate the considerable benefits and low risk that VesCellTM therapy provides to patients. Professor Tresukosol said: "These results are extremely encouraging and reaffirm our belief that VesCellTM can make a substantial and positive difference in the lives of patients suffering from severe angina pectoris.” Valentin Fulga, MD, CEO of TheraVitae, added: "Working on this landmark study with our Thai colleagues has been both exciting and fruitful. By presenting these encouraging results together at the American Heart Association meeting, we hope to have added our small contribution to the medical community’s knowledge about the utilization of adult stem cell therapies. Together with the recent publication of our scientific article in the British Journal of Hematology, we hope that our technology is starting to become acknowledged by the medical and scientific communities.”
About TheraVitae TheraVitae is a private, multinational company focused on using stem cells from the patient's own blood in order to treat a variety of disorders, especially cardiovascular diseases. The company has developed a proprietary stem cell technology, ‘VesCellTM’, that is currently being used by hospitals in Thailand and Singapore to treat patients with heart disease. TheraVitae Corporate Web Site: http://www.theravitae.com TheraVitae Thailand 36/72 PS Tower, 21/Fl., Sukhumvit 21, Klongtoey Nua, Bangkok 10110 Phone: 02-664-4290/3 Fax: 02-664-42-89 Theravitae Israel 7 Pinhas Sapir Street P.O. Box 4049, Ness Ziona 74140, Israel Phone: +972-8-9409170 Fax: +972-8-9409167
|
| < Prev | Next > |
|---|
Sponsored Links
.
Agriculture Automotive Books / Publishing Books /Publishing Business Computer Consumer Design Education Employment/Careers Engineering Environment Events/ Trade shows Finance/Money Gaming Government Home and Family Industry Insurance Latest News Legal and Law Lifestyle Maritime Media Medical Misc Music News Non Profit Politics Religion Science and research Self Help Society Sports Technology Telecoms News Trade Transportation Travel/Hospitality Wine
Created with AkoCloud 1.1 final.
Bookmark with:
What are these?